Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 27, 2026, 7:53 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Therapeutic Progesterone Clear all
Terminated Not applicable Interventional Results available

Progestin-induced Endometrial Shedding in PCOS (The PIES in PCOS Study)

NCT01718444
View directory record Official record
Conditions
Polycystic Ovary Syndrome, Infertility
Interventions
Progestin, Clomiphene Citrate
Drug
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 28, 2020 · Synced Sep 27, 2026, 7:53 AM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Modulation of Mucosal and Systemic Immunity by Hormonal Contraceptives

NCT01750476
View directory record Official record
Conditions
Initiation of Oral Contraception (OC), Initiation of Depo-Provera (DMPA), Initiation of Mirena (LNG-IUD)
Interventions
Mirena, Oral contraception, Depo-Provera
Drug
Lead sponsor
Thomas Cherpes, DVM, MD
Other
Eligibility
15 Years to 25 Years · Female only
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 6, 2014 · Synced Sep 27, 2026, 7:53 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Progesterone Effect on Individuals Diagnoses With AD and PTSD.

NCT02187224
View directory record Official record
Conditions
Alcohol Dependence, Post-Traumatic Stress Disorder (PTSD)
Interventions
Progesterone, Placebo (for Progesterone)
Drug
Lead sponsor
Yale University
Other
Eligibility
21 Years to 60 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 25, 2023 · Synced Sep 27, 2026, 7:53 AM EDT
Terminated Phase 2 Interventional Results available

Treatment of Menstrually Related Disorders With Continuous v. Interrupted Oral Contraceptives

NCT00089414
View directory record Official record
Conditions
Premenstrual Syndrome, PMS, Premenstrual Dysphoric Disorder, PMDD, Depression
Interventions
Ethinyl Estradiol/Drospirenone, Placebo, CDB 2914
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 45 Years · Female only
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 24, 2017 · Synced Sep 27, 2026, 7:53 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Talimogene Laherparepvec in Combination With Neoadjuvant Chemotherapy in Triple Negative Breast Cancer

NCT02779855
View directory record Official record
Conditions
Breast Cancer, Ductal Carcinoma, Invasive Breast Carcinoma, Invasive Ductal Breast Carcinoma
Interventions
Talimogene laherparepvec, Paclitaxel
Biological · Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years to 70 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Mar 9, 2026 · Synced Sep 27, 2026, 7:53 AM EDT
Completed Phase 3 Interventional Results available

S1202: Duloxetine Hydrochloride for Muscle/Joint Pain in Early-Stage Breast Cancer Receiving Hormone Therapy

NCT01598298
View directory record Official record
Conditions
Breast Cancer, Musculoskeletal Complications, Pain
Interventions
duloxetine hydrochloride, placebo
Drug · Other
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
Up to 120 Years · Female only
Enrollment
299 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
714
States / cities
Anchorage, Alaska • Fairbanks, Alaska • Jonesboro, Arkansas + 475 more
Source: ClinicalTrials.gov public record
Updated Dec 15, 2022 · Synced Sep 27, 2026, 7:53 AM EDT
Completed Phase 2 Interventional Results available

Treatment of Fragile-X Associated Tremor/Ataxia Syndrome (FXTAS) With Allopregnanolone

NCT02603926
View directory record Official record
Conditions
Fragile X-associated Tremor/Ataxia Syndrome
Interventions
Allopregnanolone
Drug
Lead sponsor
Randi J. Hagerman, MD
Other
Eligibility
50 Years to 85 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Dec 5, 2018 · Synced Sep 27, 2026, 7:53 AM EDT
Completed Phase 2 Interventional

Effects of Estrogen on Memory in Post-Menopausal Women and Patients With Alzheimer's Disease

NCT00006399
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Donepezil, Estrogen, Progesterone
Drug
Lead sponsor
National Center for Research Resources (NCRR)
NIH
Eligibility
45 Years to 85 Years · Female only
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2004
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Jan 14, 2009 · Synced Sep 27, 2026, 7:53 AM EDT
Terminated Phase 2 Interventional Results available

An Endometrial Cancer Study for Women With Recurrent or Persistent Endometrial Cancer

NCT03077698
View directory record Official record
Conditions
Endometrial Cancer
Interventions
Sodium Cridanimod, progestin therapy
Drug
Lead sponsor
Xenetic Biosciences, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
25
States / cities
Burbank, California • Irvine, California • Los Angeles, California + 22 more
Source: ClinicalTrials.gov public record
Updated Jun 6, 2022 · Synced Sep 27, 2026, 7:53 AM EDT
Completed Phase 2 Interventional Results available

Preoperative Cisplatin and Bevacizumab in ER-, PR-, HER2 Negative Breast Cancer

NCT00580333
View directory record Official record
Conditions
Breast Cancer
Interventions
cisplatin, bevacizumab, doxorubicin, cyclophosphamide, paclitaxel
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2020
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 25, 2021 · Synced Sep 27, 2026, 7:53 AM EDT
Completed Phase 2 Interventional Results available

Neurosteroids for Treatment of PTSD in Veterans

NCT03799562
View directory record Official record
Conditions
Posttraumatic Stress Disorder
Interventions
Pregnenolone, Placebo
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 65 Years
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Sep 27, 2026, 7:53 AM EDT
Terminated Phase 3 Interventional Accepts healthy volunteers Results available

Study Assessing Injection Pain of Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL) When Administered Via Subcutaneous Auto-injector vs Intramuscular Injection Via Needle and Syringe in Healthy Post-menopausal Women

NCT02937766
View directory record Official record
Conditions
Assessing Injection Pain of Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL) in Healthy Post-menopausal Women
Interventions
Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL)
Drug
Lead sponsor
AMAG Pharmaceuticals, Inc.
Industry
Eligibility
50 Years to 75 Years · Female only
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Pasadena, California
Source: ClinicalTrials.gov public record
Updated Apr 20, 2022 · Synced Sep 27, 2026, 7:53 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Study of CB-839 (Telaglenastat) in Combination With Talazoparib in Patients With Solid Tumors

NCT03875313
View directory record Official record
Conditions
Solid Tumor, Clear Cell Renal Cell Carcinoma, TNBC - Triple-Negative Breast Cancer, Colorectal Cancer, CRC, RCC, ccRCC
Interventions
CB-839, Talazoparib
Drug
Lead sponsor
Calithera Biosciences, Inc
Industry
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
9
States / cities
Birmingham, Alabama • Atlanta, Georgia • Iowa City, Iowa + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 16, 2022 · Synced Sep 27, 2026, 7:53 AM EDT
Completed Phase 2 Interventional Results available

Neurosteroids as Novel Therapeutic Agents for Chronic Pain in OEF/OIF Veterans

NCT01898013
View directory record Official record
Conditions
Lower Back Pain
Interventions
Pregnenolone, Placebo
Drug
Lead sponsor
Durham VA Medical Center
Federal
Eligibility
18 Years to 65 Years
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 2, 2018 · Synced Sep 27, 2026, 7:53 AM EDT
Not listed Phase 2 Interventional Accepts healthy volunteers

Follicle Stimulating Hormone (FSH) Glycosylation in Women: Effect of Estradiol

NCT03868202
View directory record Official record
Conditions
Follicle Stimulating Hormone Glycosylation, Urinary FSH21/FSH24 Ratio, Estradiol Effect
Interventions
Estradiol Transdermal Product
Drug
Lead sponsor
Eastern Virginia Medical School
Other
Eligibility
20 Years to 55 Years · Female only
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 11, 2019 · Synced Sep 27, 2026, 7:53 AM EDT
Completed Phase 1 Interventional

Progesterone for the Treatment of COVID-19 in Hospitalized Men

NCT04365127
View directory record Official record
Conditions
COVID-19, Sars-CoV2
Interventions
Progesterone 100 MG
Drug
Lead sponsor
Sara Ghandehari
Other
Eligibility
18 Years and older · Male only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 26, 2021 · Synced Sep 27, 2026, 7:53 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Clinical Trial Assessing Efficacy and Safety of Sunitinib and Exemestane in Patients With ER [Estrogen Receptor] + and/or PgR [Progesterone Receptor] + Breast Cancer

NCT00417885
View directory record Official record
Conditions
Breast Neoplasms
Interventions
exemestane, sunitinib malate
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older · Female only
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 20, 2010 · Synced Sep 27, 2026, 7:53 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Relationship Between the Menstrual Cycle and Heart Disease in Women

NCT01546454
View directory record Official record
Conditions
Coronary Heart Disease
Interventions
Ethinyl Estradiol-Levonorgestrel combination, leuprolide acetate, Estradiol, Progesterone
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
21 Years to 40 Years · Female only
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Mar 21, 2017 · Synced Sep 27, 2026, 7:53 AM EDT
Not yet recruiting Phase 1Phase 2 Interventional

Pregnenolone for Cannabis Use Disorder and Depression

NCT07685964
View directory record Official record
Conditions
Cannabis Use Disorder, Major Depressive Disorder (MDD)
Interventions
Pregnenolone
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 50 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
2
States / cities
Dallas, Texas • Richardson, Texas
Source: ClinicalTrials.gov public record
Updated Jul 5, 2026 · Synced Sep 27, 2026, 7:53 AM EDT
Recruiting Phase 2Phase 3 Interventional Accepts healthy volunteers

Focusing on the Menopausal Transition to Improve Mid-Life Women's Health

NCT06975111
View directory record Official record
Conditions
Menopause, Menopause Hot Flashes, Menopause Related Conditions, Cardiovascular
Interventions
Metformin, semaglutide, Anti-hypertensives, Lipid Lowering Medication, Life style intervention, Fezolinetant, Hormonal therapy
Drug · Behavioral
Lead sponsor
University of Colorado, Denver
Other
Eligibility
45 Years to 55 Years · Female only
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2030
U.S. locations
3
States / cities
Aurora, Colorado • Chapel Hill, North Carolina • Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Sep 27, 2026, 7:53 AM EDT
Completed Phase 1 Interventional Results available

A Treatment Study for Premenstrual Syndrome (PMS)

NCT00001259
View directory record Official record
Conditions
Premenstrual Syndrome, Menstruation Disturbances
Interventions
Leuprolide, Estradiol Patches, Progesterone, Placebo patch, Placebo injection, Placebo suppository
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 45 Years · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1992 – 2020
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 1, 2023 · Synced Sep 27, 2026, 7:53 AM EDT
Completed Phase 2 Interventional Results available

Study of Glembatumumab Vedotin (CDX-011) in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer

NCT01997333
View directory record Official record
Conditions
Metastatic gpNMB Over-expressing Triple Negative Breast Cancer
Interventions
CDX-011, Capecitabine
Drug
Lead sponsor
Celldex Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
327 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
71
States / cities
Birmingham, Alabama • Mobile, Alabama • Glendale, Arizona + 57 more
Source: ClinicalTrials.gov public record
Updated Mar 7, 2019 · Synced Sep 27, 2026, 7:53 AM EDT
Completed Phase 3 Interventional Results available

A Phase III Randomized Trial of Metformin vs Placebo in Early Stage Breast Cancer

NCT01101438
View directory record Official record
Conditions
Breast Cancer
Interventions
metformin hydrochloride, placebo
Drug · Other
Lead sponsor
Canadian Cancer Trials Group
Network
Eligibility
18 Years to 74 Years
Enrollment
3,649 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2023
U.S. locations
280
States / cities
Anchorage, Alaska • Fairbanks, Alaska • Scottsdale, Arizona + 213 more
Source: ClinicalTrials.gov public record
Updated Sep 12, 2023 · Synced Sep 27, 2026, 7:53 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Feminizing Hormone Therapy and the Rectal Mucosa Immune Environment in Transgender Women

NCT04531943
View directory record Official record
Conditions
HIV Prevention
Interventions
Estrogen, Estrogen plus Progesterone
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 59 Years
Enrollment
285 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2024
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 16, 2025 · Synced Sep 27, 2026, 7:53 AM EDT